Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tauns LaboratoriesTSE:197A +0.59%14 Days Payable is 79.50 as of Mar. 2026, which is 2% below its 10-year median of 80.73. GuruFocus rates TSE:197A with a GF Score™ of 14/100. The stock has 9 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Tauns Laboratories ranks worse than 59.12% on this metric.
The historical rank and industry rank for Tauns Laboratories's Days Payable or its related term are showing as below:
TSE:197A'
s Days Payable Range Over the Past 10 Years
Min: 48.33 Med: 80.73 Max: 182.97
Current: 58.79
During the past 5 years, Tauns Laboratories's highest Days Payable was 182.97. The lowest was 48.33. And the median was 80.73.
TSE:197A's Days Payable is ranked worse than 59.12% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.76
vs TSE:197A: 58.79
Tauns Laboratories's Days Payable
increased
from Mar. 2025 (72.60) to Mar. 2026 (79.50).
It may suggest that Tauns Laboratoriesdelayed paying its suppliers.
The historical data trend for Tauns Laboratories's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:197A vs ISRG, BDX, RMD: Days Payable Comparison
For the Medical Instruments & Supplies subindustry, Tauns Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tauns Laboratories Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tauns Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Tauns Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Tauns Laboratories's Days Payable for the fiscal year that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tauns Laboratories (TSE:197A) has a Days Payable of 79.50 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tauns Laboratories and its competitors. This is near median its historical median of 80.73. Over the past decade, Tauns Laboratories' Days Payable has ranged from 48.33 to 182.97. According to the industry distribution chart, Tauns Laboratories ranks #470 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 59.1%.
Is Tauns Laboratories' Days Payable too high?
Tauns Laboratories' current Days Payable of 79.50 is near median its 10-year median of 80.73. Over the past 10 years, this metric has ranged from a low of 48.33 to a high of 182.97. The Medical Devices & Instruments industry median Days Payable is 68.76. Tauns Laboratories' value of 79.50 is 15.6% above this industry median. Based on the distribution chart, Tauns Laboratories ranks #470 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Tauns Laboratories has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Tauns Laboratories' Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tauns Laboratories ranks #470 out of 795 companies for Days Payable. This places Tauns Laboratories in the lower half of its industry. The industry median Days Payable is 68.76. Tauns Laboratories' value of 79.50 is 15.6% above this benchmark. Historically, Tauns Laboratories' own Days Payable has ranged from 48.33 to 182.97 over the past decade. While the company's 10-year median is 80.73 vs. the industry median of 68.76, Tauns Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.76, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tauns Laboratories's current Days Payable of 79.50 is 15.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tauns Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tauns Laboratories's current Days Payable is 79.50, which is near median its own 10-year median of 80.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tauns Laboratories stock overvalued right now?
Tauns Laboratories (TSE:197A) has a current Days Payable of 79.50. The current Days Payable is 79.50, which is near median its 10-year median of 80.73 and 15.6% above the Medical Devices & Instruments industry median of 68.76. Tauns Laboratories' overall GF Score™ is 14/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Tauns Laboratories (TSE:197A), the current Days Payable is 79.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tauns Laboratories Inc is engaged in development, manufacture and sales of in vitro diagnostics and research reagents. Its product include Capilia Flu Neo, Capilia Adeno Neo, Capilia RSV Neo, Capilia hMPV, etc.
14GF Score
Get the complete analysis for TSE:197A
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:197A has been successfully added to your 
